Web: Novartis external link
Location: Basel
Discipline: Medicine/Pharmacology
Related to:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

Business Apr 23
Continuing operations saw sales, core operating income and core EPS grow (cc ) in Q1 - Net sales were USD 11.9 billion (-7%, +3% cc) - Operating income was USD 2.8 billion (-1%, +15% cc) - Core operating income (-4%, +9% cc) grew faster than sales (cc), resulting in core margin of 30.6% - Core EPS was USD 1.33 (-1%, +11% cc) - Further strengthening of USD impacted sales by -1
Medicine Apr 21

More than 27,000 Novartis associates worldwide dedicate an estimated 200,000 hours to volunteer with charitable causes in their communities - Community Partnership Day symbolizes the company's commitment to improving health and serving its local communities - Associates are partic

Medicine Apr 16

Glatopa is the first FDA-approved, substitutable generic version of Copaxone 20mg, a treatment for relapsing forms of multiple sclerosis - Novartis and Sandoz are driving access to a full range of differentiated, high-quality MS therapeutic options, complemented by a full range of s

Medicine Apr 15

Significant improvement in PFS seen with Arzerra plus chlorambucil in previously untreated patients with CLL for whom fludarabine-based therapy was inappropriate - Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed adult leukemia in Western countries, accounting for approxi

Medicine Apr 21

New FREEDOMS/FREEDOMS II sub-group analysis showed Gilenya-treated patients were six-times more likely to achieve 'no evidence of disease activity (NEDA4)' vs placebo - NEDA4 is based on four key measures of relapsing MS (RMS): relapses, MRI lesions, MS-related brain shrinkage and di

Medicine Apr 16

US Food and Drug Administration (FDA) grants approval of the AcrySof IQ ReSTOR +2.5 Diopter (D) Intraocular Lens (IOL) for sale in the US - Expands Alcon's IOL portfolio for the correction of near, intermediate and distance vision in patients undergoing cataract surgery, with

Medicine Apr 13

New analysis will confirm high efficacy of Gilenya in achieving 'no evidence of disease activity' (NEDA4) in previously-treated highly-active RMS patients - Separate analyses will show adding brain shrinkage to an existing assessment tool enhances ability to predict disability progressi

website preview


Medicine and Life Sciences
Logo Careerjet